Hemostasis Today
NewsFeed
Headlines Hematology Health Medicine VTE ASH Plasma Donation
November, 2026
November 2026
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
30  
Alefiya B.: Imagine Treating a Genetic Disorder by Giving Cells the Instructions They are Missing
Alefiya B./LinkedIn
Sep 27, 2026, 05:58

Alefiya B.: Imagine Treating a Genetic Disorder by Giving Cells the Instructions They are Missing

Alefiya B., Medical Officer at EPIC Multispecialty Hospital, Ahmedabad, shared a post on LinkedIn:

“Imagine treating a genetic disorder by giving cells the instructions they are missing.

That’s the basic idea behind gene therapy.

And a recent Nature Medicine study gives us another interesting example.

Let’s start with hemophilia B.

Hemophilia B is caused by pathogenic variants affecting the F9 gene, which is needed to produce coagulation factor IX.

When factor IX is deficient, the normal clotting process is impaired.

That’s why people with hemophilia B can experience prolonged or spontaneous bleeding.

Traditionally, treatment has involved replacing the missing clotting factor.

But gene therapy asks a different question:

What if we could give the patient’s cells a functional copy of the gene?

In the recent Phase 1 study, researchers investigated an AAV-based gene therapy carrying the Factor IX Padua variant in adolescents with hemophilia B.

The concept is fascinating:

Deliver genetic instructions → target liver cells → enable production of Factor IX

Instead of repeatedly supplying the missing protein from outside, the aim is to help the patient’s own cells produce it.

But here’s the important part about reading early research:

This was a Phase 1 clinical trial.

That means we’re looking at an early stage of clinical development, where safety, tolerability, dosing and biological activity are important considerations.

So this isn’t: ‘Hemophilia has been cured.’

It’s: ‘Researchers are testing whether a single gene-delivery approach can produce a clinically meaningful source of Factor IX.’

That’s a very different statement.

And that’s something I think we should all get better at when reading medical news:

Interesting is not equal to proven.

Promising is not equal to established.

Phase 1 is not equal to standard treatment.

But every established therapy once began as an experiment.

And that’s what makes following clinical research so fascinating.

One day, a concept exists mainly in molecular biology.

Then researchers test it in cells.

Then animals.

Then carefully selected human participants.

Then larger clinical trials.

And, if the evidence continues to support it, eventually clinical practice.

That’s how today’s “experimental” medicine can become tomorrow’s standard of care.

A question for my medical colleagues:

Which emerging area of medicine fascinates you most?

Gene therapy?
mRNA therapeutics?
CRISPR?
AI in diagnostics?
Personalized medicine?”

Alefiya B.: Imagine Treating a Genetic Disorder by Giving Cells the Instructions They are Missing

Stay updated with Hemostasis Today.

AAV-based gene therapy Alefiya B. Factor IX Health Hematology Hemophilia B Hemostasis Hemostasis News Hemostasis Today Medicine
NewsFeed